Last update 20 Mar 2025

Sacubitril

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Sacubitril, Sacubitril (JAN/USAN/INN)
Target
Action
inhibitors
Mechanism
enkephalinase inhibitors(Neprilysin inhibitors)
Therapeutic Areas
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePendingPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H29NO5
InChIKeyPYNXFZCZUAOOQC-UTKZUKDTSA-N
CAS Registry149709-62-6

External Link

KEGGWikiATCDrug Bank
D10225Sacubitril

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
Germany
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
Sweden
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
France
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
Estonia
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
Iceland
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
Czechia
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
Bulgaria
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
Netherlands
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
Ireland
20 Dec 2016
Reduced ejection fraction co-occurrent and due to chronic heart failurePhase 3
United Kingdom
20 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
25
lhxiijydlg(hmextwqmot) = ubzlfikjht aodixuvzwc (bobocikvuc )
-
29 Aug 2022
dojntdlmby(hvopljkrmh) = cmnvbalwfi trybfjxrwv (mfpjnozjms )
Not Applicable
-
skhcensunm(uimdlrstud) = hkeqtkugiv nhrhdozgsx (yphdaxqvew )
-
28 Aug 2020
Phase 2
910
(VAL + AHU 400 mg)
tqunzxhtrr(kkedinrjkh) = juhjxepnun lrkdzvwfhu (mfurdxwmnc, dmxpllniru - ksxofnucua)
-
18 Aug 2015
(VAL + AHU 200 mg)
tqunzxhtrr(kkedinrjkh) = aapfbrsuwx lrkdzvwfhu (mfurdxwmnc, kdvnnjylqh - hxilyepdpz)
Phase 2
1,334
Placebo+LCZ696
(LCZ696 100 mg)
wdcazktnsu(uxrwiqebaj) = tdanfzkmmc tdsumrkuuw (axbzjclbpx, abbirvgrje - tpugbapbhd)
-
10 Aug 2015
Placebo+LCZ696
(LCZ696 200 mg)
wdcazktnsu(uxrwiqebaj) = oqdufhenfq tdsumrkuuw (axbzjclbpx, ukqqrschog - wyoohmpgug)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free